Bausch Health Companies Inc.
$22.16B- Market cap
- $2.42B
- Debt
- +$21.04B
- Cash
- −$1.31B
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BHC stock price at premium vs WNC $6.48 current versus $1.15 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WNC's multiple
Implied fair value · at BHC's multiple
Snapshot Sep 8, 2026, 2:27 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · WNC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.15x
Capital structure 56% equity / 44% debt · EV / Revenue 0.63x · EV / EBITDA 2.67x
BHC carries the larger enterprise value at $22.16B against $975.48M; WNC trades on the lower EV / Revenue multiple (0.63x vs 2.16x); WNC on the lower EV / EBITDA (2.67x vs 9.15x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
WABASH NATIONAL CORPORATION · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
1.21x
Net debt / EBITDA
Leverage against operating earnings
8.15x
1.13x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$31.92M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
OSHKOSH CORP
BHC vs OSK
THOR INDUSTRIES INC
BHC vs THO
SAIA INC
BHC vs SAIA
LANDSTAR SYSTEM INC
BHC vs LSTR
RYDER SYSTEM INC
BHC vs R
$21.04B
$442.85M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.